2021 annual financial data

Lyell Immunopharma 2021 Operating margin

Direct answer

Operating margin was -2,016.68%.

Operating income was -214.78M USD and net income was -250.22M USD.
Operating cash flow was -126.25M USD.

Get free Lyell Immunopharma email updates.

Bullstory sends one daily email when new analysis or important company news is available.

Verified data

Revenue
10.65M USD
Operating income
-214.78M USD
Net income
-250.22M USD
Operating cash flow
-126.25M USD